Regulation of Calcium Signaling in Retinal Ganglion Cells after Nerve Injury

神经损伤后视网膜神经节细胞钙信号传导的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Ocular and traumatic brain injuries (TBI) from blunt trauma or blast injury to the head occur with high frequency on the battlefield, and they are often accompanied by multiple visual dysfunctions, acuity loss and blindness in one or both eyes. Optic neuropathies are characterized by primary injury to the optic nerve, and loss of ganglion cells and their axons. Ganglion cell death is mediated in part by excessive intracellular Ca2+ ([Ca2+]i) loads following injury. Consistent with this finding is the enhancement of retinal ganglion cell survival after optic nerve crush with the administration of Ca2+ channel antagonists, which inhibit both L- and T-type Ca2+ currents, and reduce secondary ganglion cell death. The rationale underlying the proposed studies is that reduction of ganglion cell intracellular Ca2+ levels by regulation of Ca2+ channel activity may be an important component of protective strategies for the treatment of retinal injury. Suppression of excessively elevated [Ca2+]i in ganglion cells would provide a temporal window for ganglion cell survival and axonal recovery following injury. Proposed studies will test the hypothesis that suppression of elevated [Ca2+]i following nerve injury enhances ganglion cell survival. Specific aim 1 will define the signaling role of L- and T-type Ca2+ channels, and their accessory proteins (23 and 124) in mouse retinal ganglion cells. Experiments will determine a) the expression of L- and T-type Ca2+ channels and their accessory proteins by ganglion cells, and b) characterize the physiological and biophysical properties of L- and T-type Ca2+ currents of ganglion cells. Specific aim 2 will test the hypothesis that ganglion cell Ca2+ signaling is dysregulated immediately following and several days after optic nerve crush or transection. Investigations will determine if there are short (12 and 24 hours)- and long (10 and 20 days)-term alterations of a) the expression of L- and T-type, and 23 and 124 Ca2+ channel subunits by ganglion cells, and b) membrane mechanisms that mediate Ca2+ currents and signaling in ganglion cells following optic nerve injury. Specific aim 3 will test the hypothesis that Ca2+ channel antagonists and small interfering RNA (siRNA) antisense Ca2+ channel subunit vectors regulate Ca2+ signaling, and enhance ganglion cell survival after optic nerve injury. Investigations will determine if a) the L- and T-type Ca2+ channel antagonist, lomerizine, and b) antisense T-type (CaV3.1 and CaV3.2), and 23 and 124 Ca2+ channel subunit siRNA vectors, modulate Ca2+ signaling and enhance ganglion cell survival following optic nerve injury. Proposed studies will elucidate Ca2+ signaling in normal and injured ganglion cells, and develop novel approaches for controlling elevated intracellular Ca2+ following nerve injury, which will enhance ganglion cell survival, a key step in saving vision. These studies are consistent with the health-related goals of the Veterans Adminstration to develop highly effective and novel treatments for eye injury and disease. PUBLIC HEALTH RELEVANCE: Project Narrative Traumatic brain injury (TBI) is a common casualty in the battlefield. Ocular trauma frequently occurs with TBI, which results in visual impairments, including acuity loss and blindness often due to optic nerve and retina injury. This Merit Review application will test the hypothesis that suppression of elevated intracellular Ca2+ induced by nerve injury enhances ganglion cell survival, a key step in saving vision. Planned studies will use animal models of ocular nerve injury and test novel strategies for controlling Ca2+ signaling using Ca2+ channel antagonists and antisense siRNAs for Ca2+ channels to reduce ganglion cell loss, thus setting the stage for developing new therapeutic approaches to ameliorate ocular damage and vision. These investigations are consistent with the health-related goals of the Department of Veteran Affairs to develop highly effective treatments for eye injuries and disease, and to prevent impaired vision and blindness.
描述(由申请人提供): 头部钝器伤或爆炸伤导致的眼部和创伤性脑损伤(TBI)在战场上频繁发生,通常伴有多种视觉功能障碍、一只或两只眼睛的视力丧失和失明。视神经病的特征是视神经原发性损伤以及神经节细胞及其轴突的丧失。神经节细胞死亡部分是由损伤后细胞内过量的 Ca2+ ([Ca2+]i) 负荷介导的。与这一发现一致的是,给予Ca2+通道拮抗剂可增强视神经挤压后视网膜神经节细胞的存活,该拮抗剂抑制L型和T型Ca2+电流,并减少继发性神经节细胞死亡。拟议研究的基本原理是,通过调节 Ca2+ 通道活性来降低神经节细胞细胞内 Ca2+ 水平可能是治疗视网膜损伤的保护策略的重要组成部分。抑制神经节细胞中过度升高的 [Ca2+]i 将为神经节细胞存活和损伤后轴突恢复提供时间窗口。拟议的研究将检验神经损伤后抑制 [Ca2+]i 升高可增强神经节细胞存活的假设。具体目标 1 将定义 L 型和 T 型 Ca2+ 通道及其辅助蛋白(23 和 124)在小鼠视网膜神经节细胞中的信号传导作用。实验将确定 a) 神经节细胞 L 型和 T 型 Ca2+ 通道及其辅助蛋白的表达,b) 表征神经节细胞 L 型和 T 型 Ca2+ 电流的生理和生物物理特性。具体目标 2 将检验以下假设:视神经挤压或横断后立即和几天后神经节细胞 Ca2+ 信号传导失调。研究将确定 a) 神经节细胞的 L 型和 T 型以及 23 和 124 Ca2+ 通道亚基的表达是否存在短期(12 和 24 小时)和长期(10 和 20 天)改变,以及b) 视神经损伤后神经节细胞中介导 Ca2+ 电流和信号传导的膜机制。具体目标 3 将检验 Ca2+ 通道拮抗剂和小干扰 RNA (siRNA) 反义 Ca2+ 通道亚基载体调节 Ca2+ 信号传导并增强视神经损伤后神经节细胞存活的假设。研究将确定 a) L 型和 T 型 Ca2+ 通道拮抗剂洛美利嗪和 b) 反义 T 型(CaV3.1 和 CaV3.2)以及 23 和 124 Ca2+ 通道亚基 siRNA 载体是否调节 Ca2+ 信号传导和增强视神经损伤后神经节细胞的存活率。拟议的研究将阐明正常和受损神经节细胞中的 Ca2+ 信号传导,并开发控制神经损伤后细胞内 Ca2+ 升高的新方法,这将提高神经节细胞的存活率,这是挽救视力的关键一步。这些研究与退伍军人管理局的健康相关目标一致,即开发针对眼部损伤和疾病的高效且新颖的治疗方法。 公共卫生相关性: 项目叙事 创伤性脑损伤 (TBI) 是战场上常见的伤亡情况。 TBI 经常导致眼外伤,导致视力障碍,包括视神经和视网膜损伤导致的视力丧失和失明。本次优异评审申请将检验以下假设:抑制神经损伤引起的细胞内 Ca2+ 升高可增强神经节细胞的存活率,这是挽救视力的关键一步。计划中的研究将使用眼神经损伤的动物模型,并测试使用 Ca2+ 通道拮抗剂和 Ca2+ 通道反义 siRNA 控制 Ca2+ 信号传导的新策略,以减少神经节细胞损失,从而为开发改善眼部损伤和视力的新治疗方法奠定基础。这些调查符合退伍军人事务部的健康相关目标,即开发针对眼部损伤和疾病的高效治疗方法,并防止视力受损和失明。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NICHOLAS C. BRECHA其他文献

NICHOLAS C. BRECHA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NICHOLAS C. BRECHA', 18)}}的其他基金

VRC: Reduction of Vision Loss with Early Interventions After Optic Nerve Injury
VRC:视神经损伤后早期干预可减少视力丧失
  • 批准号:
    10597946
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
BLR&D Research Career Scientist Award
BLR
  • 批准号:
    10618251
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
BLR&D Research Career Scientist Award
BLR
  • 批准号:
    10451508
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Horizontal cell signaling in the mammalian retina
哺乳动物视网膜中的水平细胞信号传导
  • 批准号:
    10090603
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Horizontal cell signaling in the mammalian retina
哺乳动物视网膜中的水平细胞信号传导
  • 批准号:
    10331735
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Horizontal cell signaling in the mammalian retina
哺乳动物视网膜中的水平细胞信号传导
  • 批准号:
    10547806
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Regulation of Calcium Signaling in Retinal Ganglion Cells after Nerve Injury
神经损伤后视网膜神经节细胞钙信号传导的调节
  • 批准号:
    7930758
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Regulation of Calcium Signaling in Retinal Ganglion Cells after Nerve Injury
神经损伤后视网膜神经节细胞钙信号传导的调节
  • 批准号:
    8397567
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Regulation of Calcium Signaling in Retinal Ganglion Cells after Nerve Injury
神经损伤后视网膜神经节细胞钙信号传导的调节
  • 批准号:
    8696777
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Transmitter Release from Mammalian Horizontal Cells
哺乳动物水平细胞的发射器释放
  • 批准号:
    8235389
  • 财政年份:
    2005
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

组织器官衰老致退行性演变多示踪剂全身动态PET显像研究
  • 批准号:
    91949121
  • 批准年份:
    2019
  • 资助金额:
    68.0 万元
  • 项目类别:
    重大研究计划
Slug参与CP-31398介导的p53突变型子宫内膜癌细胞凋亡的机制研究
  • 批准号:
    81702967
  • 批准年份:
    2017
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目
Fascin-2基因TALEN敲除小鼠渐进性听力减退的机制研究
  • 批准号:
    81771020
  • 批准年份:
    2017
  • 资助金额:
    54.0 万元
  • 项目类别:
    面上项目
N-甲基-N-亚硝脲诱导眼科疾病动物模型的潜能探索及治疗保护策略研究
  • 批准号:
    81770887
  • 批准年份:
    2017
  • 资助金额:
    56.0 万元
  • 项目类别:
    面上项目
噪声介导COX2激活抑制Nrf2/ARE信号通路在促进耳蜗毛细胞死亡中的作用机制及干预研究
  • 批准号:
    81600807
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Role of Glycosyl Ceramides in Heart Failure and Recovery
糖基神经酰胺在心力衰竭和恢复中的作用
  • 批准号:
    10644874
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and Pathology
用于血管平滑肌细胞力学生物学和病理学的仿生血管基质
  • 批准号:
    10586599
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
醋酸鲁沙来肽 (TP508) 对放射诱发的角膜病变的缓解作用
  • 批准号:
    10605739
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigating the role of CSF production and circulation in aging and Alzheimer's disease
研究脑脊液产生和循环在衰老和阿尔茨海默病中的作用
  • 批准号:
    10717111
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Mechanisms of mutant p53 reactivation
突变体 p53 重新激活的机制
  • 批准号:
    10719196
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了